Late Stage Trial Evaluating Labafenogene Marselecobac for PKU Discontinued
Synlogic has discontinued the Synpheny-3 study evaluating labafenogene marselecobac (SYNB1934) for the treatment of phenylketonuria.
Source: empr.com
Synlogic President News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Synlogic President. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Synlogic President Today - Breaking & Trending Today
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
08.02.2024 - Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to perform assessment of strategic options ... Seite 1
Source: wallstreet-online.de
Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update
10.08.2023 - Recent milestones include initiation of the pivotal Phase 3 trial, Synpheny-3, and receipt of Fast Track designation for labafenogene marselecobac as a potential treatment for PKUCAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) - Synlogic, Inc. ...
Source: wallstreet-online.de
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal
Registrational study designed to support BLA submission of first-in-class biotherapeutic Company further streamlining organization to focus resources on...
Source: globenewswire.com
Synlogic : Reports First Quarter 2023 Financial Results and Provides Business Update - Form 8-K
Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update - Phenylketonuria program on track for Phase 3 trial initiation in first half of 2023 - ... | May 11, 2023
Source: marketscreener.com